Company intelligence / Profile preview

Novel

Vaughan, Ontario, Canada

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Novel Bio has commercially launched the NBx platform, demonstrating higher plasmid DNA (pDNA) productivity and quality versus traditional E. coli systems, with early commercial revenue and expansion in services to support cell and gene therapy, mRNA, and vaccine production. The NBx platform can handle complex constructs and has been proven in scale-up collaborations with external biotech partners. The company expects robust revenue growth and profitability by FY2025.

Therapeutic areas: HematologyInfectious DiseasesRare Diseases
Modalities: Plasmid DNASynthetic DNA
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Novel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel.

Explore the full profile